Borough Park 1428 36th Street Suite 107 Brooklyn, NY 11218

Sheepshead Bay 2546 East 17th Street Fl, 1 Brooklyn, NY 11235 Long Island City 36-36 33rd Suite 311 Long Island City, NY 11106

Bronx 226 West 238th Street Bronx, NY 10463

Massapequa 97 Grand Avenue Massapequa, NY 11758

Provider

Forest Hills 64-05 Yellowstone Blvd CF104

Forest Hills, NY 11375

Gramercy 7 Gramercy Park West Lower Level New York, NY, 10003

FIDI

30 Broad Street Suite 401 New York, NY 10004

NYC E 56th & Park Midtown
120 East 56 Street
Suite 300
New York, NY 10022

E 70th St Upper East Side
225 E 70th Street
Suite 1E
New York, NY 10022
New York, NY 10021

Central Park West 115 Central Park West Suite 15 New York, NY 10023



Mission Medical

Tarrytown 555 Taxter Road 3rd Floor Elmsford, NY 10523

Port Jefferson 12 Medical Drive Suite B Port Jefferson Station, NY 11776

Staten Island 27 New Dorp Lane Staten Island, NY 10306

Fax _

Phone _____

Southampton 625 Hampton Road

Riverhead 1228 E Main Street

Suite A

Riverhead, NY 11901

Holbrook

233 Union Avenue Suite 207 Holbrook, NY 11741

Southampton, NY 11968

Rockville Centre 165 North Village Avenue Suite 133 Rockville Center, NY 11570

Manhasset 333 East Shore Road

Suite 201 Manhasset, NY 11030

New Hvde Park 1991 Marcus Ave Suite 110 Lake Success, NY, 11042

Woodbury 7600 Jericho Tpke, Lower Level, Suite C500 Woodbury NY 11797

Rozanolivizumah-noli (Ryctiggo)

PAT	ENT INFORMATION	
Name:	DOB: SEX: M 🗆 F	
ICD-10 code (required):	ICD-10 description:	
□NKDA Allergies:	Weight lbs/kg:	
R	FERRAL STATUS	
□New Referral □Referral Renewal □Medication/C	order Change \Box Benefits Verification Only \Box Discontinuation C)rder
PHYS	ICIAN INFORMATION	
Referral Coordinator Name:	Referral Coordinator Email:	
Ordering Provider:	Provider NPI:	
Referring Practice Name:	Phone: Fax:	
Practice Address:	City: State: Zip Code:	
	THERAPY ADMINISTRATION	
SPECIAL INSTRUCTIONS	 □ Rozanolixizumab-noli (Rystiggo) in 0.9% sodium chlor ■ Dose: Less than 50kg: 420mg ■ 50kg to less than 100kg: 560mg ■ 100kg and above: 840mg □ Frequency: once weekly for six weeks (one treatment cyles) □ Route: subcutaneous infusion □ Select for additional treatment cycles. □ (Indicate number of cycles) ■ Subsequent cycles may require additional insurance authorization. ■ Treatment cycles will be given 63 days from the start of the previous treatment cycle. □ Administer as a subcutaneous infusion. □ Monitor patients during administration and for 15 minut completion for clinical signs and symptoms of hypersens reactions. Order will expire one year from date signed. 	cle) es afte
NOTES/ADDITIONAL COMMENTS:		
ORDERING PROVIDER		
Signature $old X$	Date	